Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Pulmonology
•
Obstructive Lung Disease
•
Bronchiectasis
Do you utilize the bronchiectasis severity index (BSI) in your approach to managing non-CF bronchiectasis?
Related Questions
Is there a role for biologics to improve lung function in patients who have severe asthma with daily symptoms and reduced lung function but do not experience frequent exacerbations?
What patient factors prompt you to consider starting dupilumab in patients with COPD?
Will you use FeNO testing in all COPD patients to determine whether they are candidates for therapy with dupilumab?
Do you use biologic agents in patients with eosinophilic bronchiectasis?
What is your approach to inhaler therapy in a patient with asthma who cannot be on an inhaled corticosteroid due to ocular disease?
Can recurrent bilateral nasal polyps be attributed to untreated ABPA?
Do you use hypercapnia as an exclusion criteria in all patients that are being assessed for bronchoscopic lung volume reduction?
Is methacholine challenge on its way out?
Are the results of the BOREAS trial generalizable to non-white populations?
Did the low rate of COPD exacerbations in the BOREAS cohort overall confound the results of the study?
